Cytosorbents Cor (CTSO)

$0.81 +0.02 (2.55%)
Market Cap 50.95M
Revenue (ttm) 35.59M
Net Income (ttm) -20.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -58.22%
Debt to Equity Ratio 1.62
Volume 37,800
Avg Vol 98,502
Day's Range N/A - N/A
Shares Out 62.80M
Stochastic %K 84%
Beta 1.28
Analysts Strong Sell
Price Target $5.31

Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediator...

Industry: Medical Devices
Sector: Healthcare
Phone: 732 329 8885
Fax: 732 329 8650
Address:
305 College Road East, Princeton, United States
Iightning
Iightning Nov. 26 at 6:07 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 44.31% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 4:15 PM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 44.31% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 5:09 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 44.31% ROI | https://1ightning.com
0 · Reply
Steelometer
Steelometer Nov. 24 at 7:46 PM
$CTSO What is going on the Last 3 Trading Days?
2 · Reply
Iightning
Iightning Nov. 22 at 2:20 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.10 | Profit: 95.54% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 5:43 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.10 | Profit: 95.54% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 3:39 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.10 | Profit: 95.54% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 11:18 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.10 | Profit: 95.54% ROI | https://1ightning.com
0 · Reply
ZacksSCR
ZacksSCR Nov. 17 at 2:26 PM
$CTSO: CytoSorbents High Margin Revenue Growth Supports Price Target of $4.00 https://buff.ly/20ySDCO
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 8:45 PM
D. Boral Capital has adjusted their stance on CytoSorbents ( $CTSO ), setting the rating to Buy with a target price of 10.
1 · Reply
Latest News on CTSO
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

Nov 17, 2025, 5:42 PM EST - 13 days ago

Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:21 PM EST - 17 days ago

Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:05 PM EST - 17 days ago

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

Nov 11, 2025, 7:00 AM EST - 19 days ago

CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 30, 2025, 7:00 AM EDT - 4 weeks ago

CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer

Oct 28, 2025, 7:00 AM EDT - 4 weeks ago

In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

Sep 29, 2025, 7:00 AM EDT - 2 months ago

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

CytoSorbents Provides DrugSorb-ATR Regulatory Update

Sep 16, 2025, 7:00 AM EDT - 2 months ago

CytoSorbents Provides DrugSorb-ATR Regulatory Update

CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day

Sep 8, 2025, 7:00 AM EDT - 2 months ago

CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day

CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 3 months ago

CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

Aug 20, 2025, 7:00 AM EDT - 3 months ago

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 1:22 PM EDT - 4 months ago

Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:00 PM EDT - 4 months ago

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

CytoSorbents Leads a New Era in Sepsis Treatment

Jul 31, 2025, 7:00 AM EDT - 4 months ago

CytoSorbents Leads a New Era in Sepsis Treatment

CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 29, 2025, 7:00 AM EDT - 4 months ago

CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

Jul 2, 2025, 7:00 AM EDT - 5 months ago

CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

Jun 24, 2025, 7:00 AM EDT - 5 months ago

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

CytoSorbents to Participate at the Jefferies Global Healthcare Conference

May 29, 2025, 7:00 AM EDT - 6 months ago

CytoSorbents to Participate at the Jefferies Global Healthcare Conference

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

May 22, 2025, 9:27 AM EDT - 6 months ago

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:37 PM EDT - 7 months ago

Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 4:01 PM EDT - 7 months ago

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

May 1, 2025, 4:15 PM EDT - 7 months ago

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

Apr 29, 2025, 7:00 AM EDT - 7 months ago

CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

Apr 21, 2025, 7:00 AM EDT - 7 months ago

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

Apr 17, 2025, 7:00 AM EDT - 8 months ago

CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

Apr 14, 2025, 7:00 AM EDT - 8 months ago

CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants

Apr 4, 2025, 7:00 AM EDT - 8 months ago

CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants

Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:51 PM EDT - 8 months ago

Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript

CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 31, 2025, 4:15 PM EDT - 8 months ago

CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

Mar 21, 2025, 7:00 AM EDT - 9 months ago

CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

Mar 4, 2025, 7:00 AM EST - 9 months ago

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

Jan 3, 2025, 7:00 AM EST - 11 months ago

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Dec 12, 2024, 7:00 AM EST - 1 year ago

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

Nov 11, 2024, 7:30 AM EST - 1 year ago

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 1:20 PM EST - 1 year ago

Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

Oct 1, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

Aug 27, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 16, 2024, 4:05 PM EDT - 1 year ago

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 10:31 PM EDT - 1 year ago

Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

Aug 13, 2024, 4:19 PM EDT - 1 year ago

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

Aug 13, 2024, 4:18 PM EDT - 1 year ago

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

Aug 7, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

Aug 1, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website

Jul 30, 2024, 2:00 AM EDT - 1 year ago

CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website

CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress

Jul 17, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress

CytoSorbents Secures $20 Million Credit Facility

Jul 2, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents Secures $20 Million Credit Facility

CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting

Jun 5, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting

Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript

May 9, 2024, 11:01 PM EDT - 1 year ago

Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript

CytoSorbents Reports First Quarter 2024 Results

May 9, 2024, 4:17 PM EDT - 1 year ago

CytoSorbents Reports First Quarter 2024 Results

CytoSorbents to Report First Quarter 2024 Operating and Financial Results

Apr 26, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents to Report First Quarter 2024 Operating and Financial Results

Iightning
Iightning Nov. 26 at 6:07 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 44.31% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 4:15 PM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 44.31% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 5:09 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 44.31% ROI | https://1ightning.com
0 · Reply
Steelometer
Steelometer Nov. 24 at 7:46 PM
$CTSO What is going on the Last 3 Trading Days?
2 · Reply
Iightning
Iightning Nov. 22 at 2:20 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.10 | Profit: 95.54% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 5:43 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.10 | Profit: 95.54% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 3:39 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.10 | Profit: 95.54% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 11:18 AM
1ightning® Options Trade Alert (Actionable) | Buy $CTSO Dec 19 $2 Call | Enter: $0.05 Exit: $0.10 | Profit: 95.54% ROI | https://1ightning.com
0 · Reply
ZacksSCR
ZacksSCR Nov. 17 at 2:26 PM
$CTSO: CytoSorbents High Margin Revenue Growth Supports Price Target of $4.00 https://buff.ly/20ySDCO
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 8:45 PM
D. Boral Capital has adjusted their stance on CytoSorbents ( $CTSO ), setting the rating to Buy with a target price of 10.
1 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 1:08 PM
HC Wainwright & Co. updates rating for CytoSorbents ( $CTSO ) to Neutral, target set at 1 → 0.75.
0 · Reply
Kenzo71
Kenzo71 Nov. 14 at 2:49 AM
$CTSO Never a good and compelling story when cash flow break even is achieved from cost-cutting. Sales growth and revenue growth are always the much preferred approach. Unfortunately the call offered very little opportunity for future growth prior to a future FDA decision re: DrugSorb ATR and the earliest such a decision might be forthcoming is mid 2026. I would stay away from CTSO and avoid any investment here until the FDA makes a decision on DrugSorb-ATR and we have more clarity on the Company’s roll-out strategy assuming their product is approved.
0 · Reply
NJ125
NJ125 Nov. 13 at 10:25 PM
$CTSO as some expected layoffs continue. Risk increased with short window for fda resubmission and cash burn rate. Is Risk of preemptive bankruptcy filing in first half 2026 imcreasing? Confidence in senior management? Too late for Board to make changes? Expect year-end tax selling could take stock lower?!
0 · Reply
d_risk
d_risk Nov. 13 at 9:44 PM
$CTSO - Cytosorbents Corporation Common Stock - 10Q - Updated Risk Factors CTSO faces ongoing regulatory hurdles after FDA and Health Canada setbacks, heightened uncertainty around market acceptance and reimbursement for its products, and new risk of Nasdaq delisting impacting stock liquidity. #Biotechnology #StockLiquidity #ReimbursementUncertainty #MarketAcceptance #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/CTSO/10-Q/2025-11-13
0 · Reply
mspacmanbrrr
mspacmanbrrr Nov. 13 at 4:23 PM
$CTSO just found this gem
1 · Reply
hanovk68
hanovk68 Nov. 13 at 3:38 PM
$CTSO Is the bottom in? Is it time to load up the boat?
0 · Reply
Dulge_Gappana
Dulge_Gappana Nov. 12 at 2:57 PM
$CTSO wow are they selling same like magic tube like $AEMD
0 · Reply
ItalianJob10
ItalianJob10 Nov. 12 at 2:45 PM
$CTSO turd 💩 alert!
0 · Reply
Kenzo71
Kenzo71 Nov. 11 at 6:12 PM
$CTSO Will the share price drop and close below $.70/SHARE before earnings? What say you?
1 · Reply
Estimize
Estimize Nov. 10 at 11:03 AM
Wall St is expecting -0.04 EPS for $CTSO Q3 [Reporting 11/13 AMC] http://www.estimize.com/intro/ctso?chart=historical&metric_name=eps&utm_c
0 · Reply
NJ125
NJ125 Nov. 7 at 7:19 PM
$CTSO will Chan seek bankruptcy protection before annual meeting ?
1 · Reply
jacksonjohn750
jacksonjohn750 Nov. 6 at 3:05 PM
$CTSO dayum!!!
1 · Reply